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ABSTRACT
Treating hyperglycemia is a critical aspect of
managing type 2 diabetes mellitus (T2DM), but
can be especially challenging in patients from
vulnerable groups such as those with chronic
kidney disease, African Americans, and older
people. The dipeptidyl peptidase (DPP)-4
inhibitors are relatively new oral antidiabetes
drugs that have been incorporated into
treatment algorithms over the past few years
and have also been studied in these vulnerable
patients. Clinical trials with DPP-4 inhibitors
have now been reported for all these patient
groups and have demonstrated significant
improvements in measures of hyperglycemia,
with a good safety profile. Based on the current
evidence, it appears that the DPP-4 inhibitors
are worthy of consideration not only for the
most straightforward patients with T2DM, but
also for these vulnerable patients.
Keywords: African American; Chronic kidney
disease; Dipeptidyl peptidase-4 inhibitors;
Elderly; Type 2 diabetes mellitus
INTRODUCTION
The prevalence and incidence of diabetes are
increasing worldwide, largely due to changing
lifestyles characterized by reduced physical
activity, rising obesity rates, and an aging
population. In the US, diabetes is the leading
cause of kidney failure, new cases of blindness,
and non-traumatic lower limb amputations,
and is a major cause of heart disease and
stroke [1]. Diabetes currently affects 8.3% of
the US population, some 25.8 million people
[1], and type 2 diabetes mellitus (T2DM)
accounts for about 90–95% of all diagnosed
diabetes cases in adults.
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It is well documented that good glycemic
control can positively influence much of the
morbidity and mortality associated with T2DM
[2]. To manage hyperglycemia, expert
guidelines recommend treatment to a glycated
hemoglobin (HbA1c) level of below 6.5% or
below 7.0%, with recognition of the need for
individualization of treatment goals, for
example, to minimize the risks of
hypoglycemia [2–4]. The percentage of US
individuals with self-reported diabetes who
achieved an HbA1c level of \7% increased
from 44% in 1988–1994 to 52.5% in
2007–2010 [5]. Similarly, an observational
study of non-insulin–treated patients with
T2DM from Spain (n = 2,266) indicated that
45% had suboptimal HbA1c based on the \7%
criterion [6]. The International Diabetes
Management Practices Study (IDMPS) of data
from developing regions of Eastern Europe,
Asia, and Latin America reported that 36.4% of
participants with T2DM achieved an HbA1c of
\7% [7]. These data were consistent with those
from an observational study in Taiwan in which
the percentage of patients achieving the \7%
goal increased from 32.4% in 2006 to 34.5% in
2011 [8]. Taken together, these findings suggest
that there has been some success in putting
guidelines into practice, but that approximately
one-third to one-half of patients still fail to
achieve HbA1c levels below 7.0% [5–8].
Furthermore, the progressive deterioration of
b-cell function, irrespective of pharmacological
interventions to treat hyperglycemia, leads to
an almost inevitable need for intensification of
treatment [2]. There is, therefore, a recognized
need for new therapeutic options that are well
tolerated over the long term and have a durable
effect.
The dipeptidyl peptidase (DPP)-4 inhibitors are
relatively new drugs that may help meet the need
for these types of treatments, and following
extensive testing in phase 3 clinical trials, these
agents have now been included in treatment
recommendations in all major diabetes
guidelines. This review will provide a brief
overview regarding the positioning of DPP-4
inhibitors in the context of major clinical
guidelines. Furthermore, since the majority of
patients in phase 3 trials are relatively young and
healthy, an additional objective of this review is
to consider the DPP-4 inhibitors for the treatment
of T2DM in more vulnerable patient populations,
namely those with chronic kidney disease (CKD),
African Americans, and older people. Current
guidelines for these patients, and the clinical trials
conducted with DPP-4 inhibitors in these groups,
will be reviewed.
METHODS
This was a non-systematic review of the
literature. A search of English-language
literature was performed using PubMed and
without imposing any time limitations. Search
terms included combinations of the following:
‘type 2 diabetes’, ‘DPP-4 inhibitors’, ‘chronic
kidney disease’, ‘end-stage renal disease’, ‘renal
impairment’, ‘African American’, and ‘elderly’.
Articles and abstracts relevant to the subject
were included. Bibliographies from retrieved
articles were also searched for relevant articles.
Additional references known to the author were
also included. The analysis in this article is based
on previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
DPP-4 INHIBITORS
The DPP-4 inhibitors improve glycemic control
mainly via potentiation of the incretin effect,
that is, the postprandial augmentation of
insulin secretion by the gastrointestinal
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incretin hormones glucagon-like peptide (GLP)-
1 and gastric inhibitory polypeptide (GIP).
Increases in GLP-1 levels appear to account for
the majority of the DPP-4 inhibitors’ effects [9].
In addition to enhancing glucose-dependent
insulin secretion, GLP-1 suppresses glucose-
dependent glucagon secretion, inhibits gastric
emptying, and reduces appetite and food intake
[10]. It has long been known that the incretin
effect is blunted in patients with T2DM,
generating interest in therapies that target the
incretin system [10]. Native GLP-1 itself cannot
be used in therapy due to its rapid degradation
by the DPP-4 enzyme, resulting in a half-life of
less than 2 min. Nevertheless, therapeutic
approaches for enhancing incretin action have
been developed and include degradation-
resistant GLP-1 receptor agonists, and
increasing levels of GLP-1 indirectly by
inhibition of DPP-4 [10].
Four DPP-4 inhibitors are approved in the
US: sitagliptin (approved 2006), saxagliptin
(approved 2009), linagliptin (approved 2011),
and alogliptin (approved 2013). Vildagliptin is
another DPP-4 inhibitor that has been
extensively studied and is currently available
in the European Union and Japan. There are
also other DPP-4 inhibitors in earlier stages of
development that may become available over
the coming years. Although all of the DPP-4
inhibitors share the same mechanism of action,
they have different chemical and
pharmacokinetic properties, which may
translate into clinical options with distinct
profiles.
Place in Current Guidelines
In clinical trials, all available DPP-4 inhibitors
have been shown to improve glycemic control,
with clinically meaningful reductions in HbA1c
[11]. Furthermore, they are well tolerated, are
associated with a low risk of hypoglycemia, and
have a favorable weight profile [11]. As evidence
accumulates for their effectiveness, the DPP-4
inhibitors have been incorporated into
numerous guidelines available for the
management of patients with T2DM. A
consensus statement and algorithm issued by
the American Association of Clinical
Endocrinologists (AACE) in 2013 describes
several options for monotherapy and
variations of combination therapy [4]. The
DPP-4 inhibitors are placed among
monotherapy options for patients with an
entry level HbA1c of \7.5%. As with American
Diabetes Association (ADA) and European
Association for the Study of Diabetes (EASD)
recommendations, metformin is recommended
as the first-line choice where not
contraindicated. The AACE algorithm also
places DPP-4 inhibitors as an option for the
second component of initial dual or triple
therapy in patients with entry HbA1c levels of
C7.5% or C9%, respectively. The DPP-4
inhibitors may also be considered as the first
component of dual or triple therapy for patients
for whom metformin is contraindicated. The
detailed AACE guidelines issued in 2011 noted
that DPP-4 inhibitors, along with metformin,
sulfonylureas, glinides, and thiazolidinediones,
are all approved for use in combination with
insulin [3]. However, the guidelines also
highlight a raised potential for hypoglycemia
when a sulfonylurea or a glinide is used with
insulin, as well as several adverse effects
associated with thiazolidinediones in
combination with insulin, suggesting that
these combinations should be carefully
considered.
The ADA and EASD also issued a position
statement on the management of
hyperglycemia in T2DM [12]. The ADA/EASD
guidelines are less prescriptive, discuss
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advantages and disadvantages of all
antidiabetes medicines, and highlight the need
for individualization of treatment. In the
general recommendations outlined in the
guidelines, DPP-4 inhibitors are positioned
alongside sulfonylureas, thiazolidinediones,
GLP-1 agonists, and insulin, as a second-line
add-on to metformin. They are prioritized along
with GLP-1 agonists as an add-on to metformin
when the goal is to avoid weight gain, and with
GLP-1 agonists and thiazolidinediones when
the goal is to avoid hypoglycemia. When
metformin is not an option for first-line
therapy, the ADA/EASD guidelines suggest a
sulfonylurea, thiazolidinedione, DPP-4
inhibitor, or GLP-1 agonist.
Among other guidelines, the International
Diabetes Federation [13], the National Institute
for Health and Clinical Excellence [14], and the
US Department of Veterans Affairs/Department
of Defense [15], all suggest DPP-4 inhibitors as
an alternative add-on to metformin, when a
sulfonylurea is contraindicated or when
hypoglycemia is a concern.
Guidelines are typically based on
randomized trials that recruit the most
straightforward patients. In the past, this is
known to have led to underuse of new
treatments in the very patients who could
benefit the most. For example, African
Americans are generally not well represented
in clinical trials [16], and this, in addition to
other factors, resulted in lower use of
angiotensin-converting enzyme (ACE)-
inhibitors (ACEI) for the treatment of
hypertension in African Americans [17].
Conversely, therapies should not be used in
patients when evidence is lacking. Therefore, in
light of a number of recently reported studies, it
is worthwhile examining the available evidence
for use of DPP-4 inhibitors in vulnerable patient
groups.
Use in Patients with Chronic Kidney Disease
The National Kidney Foundation (NKF) Kidney
Disease Outcomes Quality Initiative (KDOQI)
defines CKD by the presence of kidney damage
or a glomerular filtration rate (GFR) \60 mL/
min/1.73 m2 for 3 months or more [18]. It also
classifies the stages of CKD as ranging between
Stage 1 (kidney damage with normal or
increased GFR) and Stage 5 (kidney failure).
End-stage renal disease (ESRD) is included
under Stage 5 of the KDOQI classification and
is defined as irreversible decline in kidney
function that is severe enough to be fatal
in the absence of dialysis or transplantation
[18].
Diabetes is considered a major risk factor for
CKD, with nearly 40% of adults with T2DM
having some degree of CKD [19, 20].
Furthermore, 44% of new ESRD cases in the
US in 2010 had a primary diagnosis of diabetes
[21]. While managing hyperglycemia is a key
goal in patients with CKD, glycemic targets and
choice of therapy in this patient group warrant
special consideration. For example, metformin,
normally the first choice of treatment for
T2DM, is renally excreted, and decreased
kidney function may increase the risk of lactic
acidosis with its use. Current prescribing
guidelines in the US contraindicate metformin
when serum creatinine levels are C1.4 mg/dL in
women and C1.5 mg/dL in men [22].
Furthermore, many other common
antidiabetes drugs are renally excreted and
have a prolonged half-life in patients with
CKD, thereby increasing the risk of
hypoglycemia. Recent guidelines for diabetes
and CKD state that HbA1c targets of \7.0% are
not recommended in patients with diabetes
who are at risk for hypoglycemia, including
those treated with insulin or sulfonylureas and/
or who have advanced CKD. They suggest
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instead extending HbA1c targets above 7.0% for
patients with diabetes who are at risk of
hypoglycemia and have clinically significant
comorbidities or limited life expectancy [23].
The glucose-dependent stimulation of
insulin release by the DPP-4 inhibitors confers
a low risk of hypoglycemia [24], suggesting
potential value for managing hyperglycemia in
patients with T2DM and CKD. Indeed, a
number of trials that specifically investigated
DPP-4 inhibitors in renally impaired
populations have been reported (Table 1) or
completed with results anticipated in the near
future (Table 2) [25–36]. Efficacy and safety data
from the clinical trials reported to date are
encouraging, and the DPP-4 inhibitors were
generally well tolerated (Table 1). With
appropriate caution, the DPP-4 inhibitors can
be used in patients with all degrees of renal
insufficiency, including ESRD, although dosage
reduction is needed for saxagliptin, sitagliptin,
and vildagliptin. Linagliptin can be used
without adjustment, since it is not renally
excreted (Table 3) [37–41].
Individuals with concomitant T2DM and
CKD may be receiving an ACEI for
management of hypertension because this
class of medications may reduce cardiovascular
events and protect the kidney [2]. A small
increase in the risk of angioedema has been
observed in patients taking concurrent ACEI
and vildagliptin, but the authors were unable to
determine a class effect through review of
postmarketing surveillance data and the
literature [42]. It is postulated that ACE
inhibition shifts the metabolism of the
angioedema-associated vasoactive peptides
bradykinin and substance P to the secondary
DPP-4 pathway [42, 43]. However, little
information is available regarding the clinical
relevance and frequency of ACEI and DPP-4
inhibitor interactions [43]. On the other hand,
the propensity for drug–drug interactions
mediated via the p-glycoprotein (P-gp)
intestinal transport system and related to
cytochrome P450 3A4 (CYP3A4) metabolism
have been well characterized, with some
variation among the DPP-4 inhibitors [37–41,
44]. Generally, the DPP-4 inhibitors have
limited drug–drug interactions via these
mechanisms [37–41, 44]. However, alternatives
to strong inducers of CYP3A4 or P-gp (e.g.
rifampin) are strongly recommended when
linagliptin is to be administered [38]. In
addition, a reduction of the saxagliptin dosage
to 2.5 mg once daily is recommended when
coadministered with strong CYP3A4/5
inhibitors (e.g. ketoconazole) [39].
Use in African Americans
African Americans are at an increased risk of
T2DM, with a prevalence of diabetes
approximately double that of the white
population [45]. This group also has an
increased rate of complications and greater
disability from complications, as well as poorer
glycemic control and quality of care [46–50].
The pathophysiology of T2DM may be different
in African Americans than in other populations,
with studies suggesting that insulin resistance is
higher in minority populations [51]. There are
various theoretical reasons to consider DPP-4
inhibitors in African Americans. First, a small
number of studies report racial disparities in
GLP-1 levels that may have implications for
efficacy of DPP-4 inhibitors in African
Americans. Two studies observed that African
American adolescents had lower GLP-1
concentrations than white adolescents [52, 53].
In contrast, an earlier investigation reported
that obese African American adults had
significantly higher fasting and post-challenge
GLP-1 concentrations than obese white adults
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[54]. Further studies are warranted to confirm
racial differences in GLP-1 levels and to
investigate any therapeutic implications.
In the meantime, there are other reasons why
DPP-4 inhibitors may be a good option for this
population. A significant proportion of African
Americans are overweight or obese, with the
prevalence of overweight and obesity combined
at 76.6% (69.9% in men, 82.1% in women), and
the prevalence of obesity at 49.6% (38.8% in
men, 58.6% in women) [55]. Overweight and
obesity are risk factors for insulin resistance, and
all guidelines therefore recommend losing
weight for overweight or obese patients with
T2DM [2–4]. In contrast to insulin and some oral
antidiabetes drugs that can result in weight gain,
the weight-neutral DPP-4 inhibitors may
therefore be an appropriate option for patients
who are overweight or obese. African Americans
are also disproportionally affected by CKD and
ESRD [56, 57], with the rate of new ESRD cases
being 3.4 times higher among this group than
among the white population [21]. The presence
of renal impairment has implications for
diabetes management, but as discussed in the
previous section, the DPP-4 inhibitors remain a
viable choice in this setting.
Despite the prevalence of T2DM in African
Americans, there is limited clinical trial
information for this population. While the
DPP-4 inhibitors seem theoretically
appropriate for use in African Americans with
T2DM, this group is characterized by higher
HbA1c levels than other populations [58]. With
predicted HbA1c reductions ranging between
0.4 and 1.0% with this class of drugs [11, 59],
monotherapy would likely not be suitable for all
patients, although larger reductions are
expected in patients with higher baseline
HbA1c [60].
Based on composite analyses of available
pharmacokinetic data, the prescribing
information for all DPP-4 inhibitors state that
no dose adjustment is necessary based on race
[37–41], but to date only linagliptin has been
specifically investigated in African Americans. A
phase 1 study (NCT00935220) assessing its
pharmacodynamic and pharmacokinetic
profile in African Americans with T2DM for
7 days, supported linagliptin 5 mg/day as
effective for controlling blood glucose levels
[61]. A subsequent phase 3 trial (NCT01194830)
evaluated its efficacy and safety in black/African
Americans with T2DM over 24 weeks [62]. In
this study, 226 patients were randomized to
linagliptin or placebo, and HbA1c levels were
measured every 6 weeks. A statistically
significant and clinically relevant difference
Table 3 Recommended dosing of DPP-4 inhibitors in the presence of CKD
First approved Standard dose Recommended dose in context of chronic kidney disease
Alogliptin [37] US (2013) 25 mg once daily CrCl C30 to\60 mL/min (moderate RI): 12.5 mg once daily
CrCl\30 mL/min (severe/ESRD): 6.25 mg once daily
Linagliptin [38] US (2011) 5 mg once daily No dose adjustment required
Saxagliptin [39] US (2009) 5 mg once daily CrCl B50 mL/min (moderate/severe/ESRD): 2.5 mg once daily
Sitagliptin [40] US (2006) 100 mg once daily CrCl C30 to\50 mL/min (moderate RI): 50 mg once daily
CrCl\30 mL/min (severe/ESRD): 25 mg once daily
Vildagliptin [41] EU (2007) 50 mg twice daily CrCl\50 mL/min (moderate/severe/ESRD): 50 mg once daily
CrCl creatinine clearance, ESRD end-stage renal disease, RI renal impairment
1074 Adv Ther (2013) 30:1067–1085
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between treatment groups was found for the
change in HbA1c after 24 weeks [placebo-
adjusted mean change of -0.58% (95% CI -
0.91 to -0.26%; P\0.001)], indicating the
superiority of linagliptin compared with
placebo in reducing HbA1c in black/African
American patients [63]. Furthermore, as
expected from pivotal trials, linagliptin was
well tolerated and weight neutral, with a low
rate of hypoglycemic events, confirming its
safety profile as well as efficacy in African
American patients with T2DM [63].
Use in Older People
The latest census figures in the US indicate that
people aged 65 years and older represent 13.2%
of the population [64], and this proportion is
expected to grow to just over 20% by 2050 [65].
The incidence of T2DM in older people is a
major public health concern, and in 2010
almost 27% of people aged 65 years and older
in the US had diabetes [1]. Clinical
management of the older patient with T2DM
is often challenging as these patients have an
increased prevalence of cardiovascular risk
factors, diabetes-related complications, and
comorbidities such as renal impairment,
congestive heart failure, cognitive impairment,
and physical disability. Furthermore, they are
often prescribed multiple medications, which
further complicates treatment strategies and
may reduce adherence [66–68]. The older
T2DM patient population is, however, a highly
heterogeneous group with a broad spectrum of
disease duration, life expectancy, and
comorbidities. A position statement issued by
the International Association of Gerontology
and Geriatrics (IAGG), the European Diabetes
Working Party for Older People (EDWPOP), and
the International Task Force of Experts in
Diabetes, recommends that an HbA1c target
range of 7.0–7.5% should generally be aimed for
in older patients. The caveat to this statement is
that individual comorbidities, and cognitive
and functional status, should be considered
when determining goals. Furthermore, this
position statement highlights hypoglycemia in
older people as a highly prevalent and under-
recognized disorder with severe consequences
such as falls, cognitive impairment, and
hospital admission [69].
The heterogeneity of this population is also
addressed by the ADA. Their guidelines
recommend that the same glycemic targets be
applied to otherwise healthy older people as to
younger people with diabetes; and a less
ambitious target be applied to patients with
more complicated conditions that include
multiple comorbidities, a high level of
functional dependency, and limited life
expectancy [2, 70].
The DPP-4 inhibitors have generated
particular interest for the treatment of older
patients with T2DM for a number of reasons,
namely their convenient oral dosing, the
importance of avoiding hypoglycemia in the
elderly, and considerations of declining renal
function in this patient group. Indeed, the
recent position statement mentioned above
states that in selected older patients not at
target or where there is poor tolerance to
glucose-lowering agents, the use of DPP-4
inhibitors can be considered as second-line
therapy [69]. The ADA acknowledges the few
side effects associated with DPP-4 inhibitors in
the context of their use in older patients;
however, it also notes that their costs may be
a barrier to some older patients [2]. The
prescribing information available for these
drugs generally agree that no overall
differences in safety or effectiveness were
observed between patients aged 65 years and
over and younger patients [37–41]. However,
Adv Ther (2013) 30:1067–1085 1075
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caution is advised in the context of older
patients, who are more likely to have
decreased renal function, and dosing
adjustments are recommended for all DPP-
inhibitors, except linagliptin, under these
circumstances.
Three studies that prospectively assessed
DPP-4 inhibitors in older patients with T2DM
have been reported [71–73] (Table 4). A double-
blind, randomized, active-controlled study
compared vildagliptin with metformin over
24 weeks in 335 drug-naı¨ve patients with
T2DM aged C65 years. In this study, 41% of
patients had normal renal function, 57% had
mild renal insufficiency, and less than 2% had
moderate renal insufficiency. The investigation
showed that vildagliptin is an effective and
well-tolerated treatment option in this group,
demonstrating non-inferiority to metformin in
terms of glycemic control, but superior
gastrointestinal tolerability [71]. The second
trial, a double-blind, randomized, placebo-
controlled study of sitagliptin over 24 weeks in
206 patients with T2DM aged C65 years,
concluded that sitagliptin significantly and
rapidly improved glycemic control and was
well tolerated in this group [72]. This study
also included patients with moderate renal
insufficiency (22%), but excluded those with
severe renal insufficiency (estimated creatinine
clearance \35 mL/min). Finally, a randomized,
double-blind, placebo-controlled study
investigated the efficacy and safety of
linagliptin in 241 patients aged C70 years with
T2DM and insufficient glycemic control despite
metformin and/or sulfonylurea and/or insulin
therapy [73]. The majority of patients in this
study had either normal renal function (21%) or
mild renal insufficiency (52%); 26% of patients
had moderate renal insufficiency and less than
2% had severe renal insufficiency. This study
concluded that linagliptin was effective and
well tolerated in elderly patients and no safety
concerns were identified.
Other pooled analyses, subgroup analyses,
and systematic reviews also showed that DPP-4
inhibitors in the older T2DM population were
generally effective and well tolerated [74–81].
However, some studies show that when DPP-4
inhibitors are concomitantly administered with
insulin or a sulfonylurea, there is an elevated
risk of hypoglycemia over the concomitant
administration of placebo with insulin or a
sulfonylurea [82, 83]. In contrast, a pooled
analysis evaluating linagliptin as add-on
therapy to basal insulin showed no increased
risk of hypoglycemia with the DPP-4 inhibitor
[81]. Given the serious consequences of
hypoglycemic events in older patients, the
combination of a DPP-4 inhibitor with a
sulfonylurea is perhaps ill advised; in fact, the
IAGG, EDWPOP, and the International Task
Force of Experts in Diabetes recommend that
sulfonylurea therapy should be avoided in any
older patient at risk of hypoglycemia [69].
Interestingly, there is also preliminary
evidence that DPP-4 inhibitors are associated
with a reduced risk of bone fractures compared
with placebo or other treatments [84]. Recent
evidence shows that T2DM is an independent
risk factor for bone fracture [85, 86] and that
older people with T2DM are at an increased risk
of hip fractures [87, 88]. Furthermore, clinical
trial data suggest that DPP-4 inhibitors may be
associated with a lower risk of stroke compared
with other therapies [89]. Patients with diabetes
have an increased risk of ischemic stroke, a risk
that increases in correlation with duration of
diabetes [90, 91], therefore posing a particular
concern for elderly patients with long-standing
T2DM. If confirmed, these risk reductions will
provide further compelling reasons to consider
DPP-4 inhibitors in older patients. Various
prospective studies of glycemic outcomes in
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this population are underway or recently
completed (Table 5), and their findings will
provide further valuable safety and efficacy
data about DPP-4 inhibitors in this group, and
may also allow for additional pooled analyses
of outcomes of interest such as fracture.
Furthermore, ongoing cardiovascular safety
trials with the DPP-4 inhibitors (see below
and Table 6) are expected to include
substantial numbers of elderly patients,
providing valuable outcome information in
this particular population. In particular,
patients aged C70 years qualify for inclusion
in the CAROLINA (Cardiovascular Outcome
Study of Linagliptin Versus Glimepiride in
Patients With Type 2 Diabetes) trial, a large-
scale study that aims to investigate the effects
of linagliptin on cardiovascular morbidity and
mortality.
Future Directions
Safety data for DPP-4 inhibitors based on
registration studies are reassuring, with
various meta-analyses indicating a benign and
perhaps beneficial cardiovascular safety profile
for the class [92–96]. However, their long-term
impact on cardiovascular outcomes has yet to
be firmly established by clinical trials. To
address this, several large-scale trials,
including EXAMINE (Examination of
Cardiovascular Outcomes with Alogliptin
versus Standard of Care), CARMELINA
(Cardiovascular and Renal Microvascular
Outcome Study With Linagliptin in Patients
With Type 2 Diabetes Mellitus at High Vascular
Risk), CAROLINA, SAVOR-TIMI 53 (The
Saxagliptin Assessment of Vascular Outcomes
Recorded in Patients with Diabetes Mellitus—
Thrombolysis in Myocardial Infarction 53
trial), and TECOS (Sitagliptin Cardiovascular
Outcome Study), have been designed to
investigate the effects of DPP-4 inhibitors on
cardiovascular morbidity and mortality
(Table 6), and provide further insight into the
efficacy, safety, and durability of response of
these drugs. Results from the first two
completed trials, EXAMINE and SAVOR-TIMI
53, demonstrated no change in the risk of the
composite major adverse cardiovascular event
endpoint with either alogliptin or saxagliptin
compared with placebo when added to the
standard of care [97, 98]. In EXAMINE, the
point estimate for the hazard ratio (HR) was\1
and the upper limit of the 95% CI was \1.3,
which was the pre-specified non-inferiority
safety margin (HR with alogliptin, 0.96; upper
boundary of the one-sided repeated CI, 1.16;
P\0.001 for non-inferiority) [97]. Similarly in
SAVOR-TIMI 53, saxagliptin met the non-
inferiority criterion but did not demonstrate
cardiovascular superiority versus placebo (HR
with saxagliptin 1.00, 95% CI 0.89–1.12,
P = 0.99 for superiority, P\0.001 for non-
inferiority) [98].
CONCLUSIONS
The DPP-4 inhibitors are clearly emerging as a
useful treatment option in the general T2DM
population and, as additional trials are reported,
it appears their characteristics may make them
particularly suitable for more vulnerable patient
populations. DPP-4 inhibitors can be used in
the context of CKD, a significant consideration
for any antidiabetes treatment. They are also
weight neutral, an important aspect when
making therapy choices with a patient who is
overweight or obese. Furthermore, their
straightforward dosing and low risk of
hypoglycemia are desirable characteristics,
particularly when choosing treatments for
older patients.
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For various reasons, physicians may be
cautious about using new therapies in
vulnerable patient populations. However,
these groups could potentially benefit from
new treatments, and caution can be balanced
by close monitoring and vigilance to ensure
that all groups benefit from therapeutic
advances. Given the variable progression of
T2DM and the heterogeneity even within
subgroups of patients, individualizing therapy
will always be essential. Nevertheless, awareness
of the typical issues for these high-risk groups
may help physicians who are considering
therapeutic options, including the DPP-4
inhibitors, when developing specific
management strategies for individual patients.
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